SCHEMBL23999941

SCHEMBL23999941

O=Cc1ccc(Nc2ccnc3ccc(N4CCC4)cc23)nc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK2 P49137 11/20 0.52
TRIM24 O15164 1/20 0.39
TRIM33 Q9UPN9 1/20 0.39
IP6K1 Q92551 3/20 0.39
IP6K3 Q96PC2 1/20 0.39
ALDH1A1 P00352 2/20 0.38
RET P07949 1/20 0.38
KDR P35968 1/20 0.38
CSNK1A1 P48729 1/20 0.38
CDK8 P49336 1/20 0.38
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38
ACVR1 Q04771 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
DYRK1B Q9Y463 1/20 0.38
KDM4E B2RXH2 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
SLC2A1 P11166 1/20 0.38
MITF O75030 1/20 0.38
RAD52 P43351 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23999949 0.91 MAPKAPK2 (0.52) MAPKAPK2RETKDRCSNK1A1CDK8
SCHEMBL23999868 0.87 MAPKAPK2 (0.46) MAPKAPK2RETKDRCSNK1A1CDK8
SCHEMBL23999906 0.85 MAPKAPK2 (0.69) MAPKAPK2SLC2A1MITFRAD52
SCHEMBL23999537 0.82 MAPKAPK2 (0.43) MAPKAPK2IP6K1IP6K3RETKDR
SCHEMBL23999854 0.80 IP6K1 (0.43) MAPKAPK2IP6K1IP6K3ALDH1A1RET
SCHEMBL23999535 0.79 NPC1 (0.43) MAPKAPK2RETKDRCSNK1A1CDK8
SCHEMBL23999939 0.79 IP6K1 (0.45) MAPKAPK2IP6K1IP6K3RETKDR
SCHEMBL23999822 0.78 MAPKAPK2 (0.52) MAPKAPK2SLC2A1MITFRAD52
SCHEMBL23999853 0.77 NPC1 (0.43) MAPKAPK2RETKDRCSNK1A1CDK8
SCHEMBL23999819 0.76 MAPKAPK2 (0.41) MAPKAPK2IP6K1ALDH1A1CDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295114-A1 AKT3 MODULATORS Georgiamune Inc. 2023-09-21 US disclosed
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 US disclosed
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 US disclosed
WO-2023081854-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2023-05-11 WO disclosed
WO-2021226519-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2021-11-11 WO disclosed
WO-2021226517-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2021-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295114-A1 AKT3 MODULATORS AKT3, AKT2, MTOR MAPKAPK2 151/4885TRIM24 4231/4885TRIM33 2462/4885
US-20230183226-A1 AKT3 MODULATORS AKT3, AKT2, MTOR MAPKAPK2 138/4885TRIM24 4268/4885TRIM33 2570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.